A Cancer Research UK Phase I Trial of AZD3965, a monocarboxylate transporter 1 inhibitor (MCT1) in patients with advanced cancer
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2018
At a glance
- Drugs AZD 3965 (Primary)
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Gastric cancer; Lymphoma; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- 31 Aug 2018 Biomarkers information updated
- 12 Jul 2018 Planned number of patients changed from 64 to 63.
- 12 Jul 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2019.